[English] 日本語

- PDB-9msy: G002-480-0546 Fab in complex with V703-0537_T278M_L14 SOSIP and B... -
+
Open data
-
Basic information
Entry | Database: PDB / ID: 9msy | ||||||
---|---|---|---|---|---|---|---|
Title | G002-480-0546 Fab in complex with V703-0537_T278M_L14 SOSIP and BG18 Fab | ||||||
![]() |
| ||||||
![]() | VIRAL PROTEIN/IMMUNE SYSTEM / G002 / clinical trial / HIV-1 / VRC01 / human antibody / vaccine / Env / VIRAL PROTEIN / VIRAL PROTEIN-IMMUNE SYSTEM complex | ||||||
Biological species | ![]() ![]() ![]() | ||||||
Method | ELECTRON MICROSCOPY / single particle reconstruction / cryo EM / Resolution: 3.4 Å | ||||||
![]() | Phulera, S. / Ozorowski, G. / Ward, A.B. | ||||||
Funding support | ![]()
| ||||||
![]() | ![]() Title: Vaccination with mRNA-encoded nanoparticles drives early maturation of HIV bnAb precursors in humans. Authors: Jordan R Willis / Madhu Prabhakaran / Michelle Muthui / Ansuya Naidoo / Troy Sincomb / Weiwei Wu / Christopher A Cottrell / Elise Landais / Allan C deCamp / Nahid R Keshavarzi / Oleksandr ...Authors: Jordan R Willis / Madhu Prabhakaran / Michelle Muthui / Ansuya Naidoo / Troy Sincomb / Weiwei Wu / Christopher A Cottrell / Elise Landais / Allan C deCamp / Nahid R Keshavarzi / Oleksandr Kalyuzhniy / Jeong Hyun Lee / Linda M Murungi / Wilfrida A Ogonda / Nicole L Yates / Martin M Corcoran / Swastik Phulera / Joel Musando / Amanda Tsai / Gabrielle Lemire / Yiakon Sein / Michael Muteti / Praveen Alamuri / Jennifer A Bohl / Drienna Holman / Sunny Himansu / Brett Leav / Caroline Reuter / Li-An Lin / Baoyu Ding / Chunla He / Walter L Straus / Kellie J MacPhee / Isabel Regadas / Diana V Nyabundi / Ruth Chirchir / Aggrey Anzala / John N Kimotho / Caleb Kibet / Kelli Greene / Hongmei Gao / Erica Beatman / Kiara Benson / Dominick Laddy / David M Brown / Rhianna Bronson / Jalen Baptiste / Suprabhath Gajjala / Zahra Rikhtegaran-Tehrani / Alison Benner / Mukundhan Ramaswami / Danny Lu / Nushin Alavi / Sonya Amirzehni / Michael Kubitz / Ryan Tingle / Erik Georgeson / Nicole Phelps / Yumiko Adachi / Alessia Liguori / Claudia Flynn / Katherine McKenney / Xiaoya Zhou / D Collins Owuor / Sharon Owuor / Soo-Young Kim / Michael Duff / Ju Yeong Kim / Grace Gibson / Sabyasachi Baboo / Jolene Diedrich / Torben Schiffner / Marisa Shields / Mabela Matsoso / Jennifer Santos / Kristen Syvertsen / Allison Kennedy / Melissa Schroeter / Johan Vekemans / John Yates / James C Paulson / Ollivier Hyrien / Adrian B McDermott / Pholo Maenetje / Julien Nyombayire / Etienne Karita / Rosine Ingabire / Vinodh Edward / Vincent Muturi-Kioi / Janine Maenza / Adrienne E Shapiro / M Juliana McElrath / Srilatha Edupuganti / Barbara S Taylor / David Diemert / Gabriel Ozorowski / Richard A Koup / David Montefiori / Andrew B Ward / Gunilla Karlsson Hedestam / Georgia Tomaras / Devin J Hunt / Daniel Muema / Devin Sok / Dagna S Laufer / Sarah F Andrews / Eunice W Nduati / William R Schief / ![]() ![]() ![]() ![]() ![]() Abstract: A leading HIV vaccine strategy requires a priming immunogen to induce broadly neutralizing antibody (bnAb) precursors, followed by a series of heterologous boosters to elicit somatic hypermutation ...A leading HIV vaccine strategy requires a priming immunogen to induce broadly neutralizing antibody (bnAb) precursors, followed by a series of heterologous boosters to elicit somatic hypermutation (SHM) and produce bnAbs. In two randomized, open-label phase 1 human clinical trials, IAVI-G002 in the United States and IAVI-G003 in Rwanda and South Africa, we evaluated the safety and immunogenicity of mRNA-encoded nanoparticles as priming immunogens (both trials) and first-boosting immunogens (IAVI-G002). The vaccines were generally safe and well tolerated, except 18% of IAVI-G002 participants experienced skin reactions. Priming induced bnAb precursors with substantial frequencies and SHM, and heterologous boosting elicited increased SHM, affinity, and neutralization activity toward bnAb development. The results establish clinical proof of concept that heterologous boosting can advance bnAb-precursor maturation and demonstrate bnAb priming in Africa where the HIV burden is highest. | ||||||
History |
|
-
Structure visualization
Structure viewer | Molecule: ![]() ![]() |
---|
-
Downloads & links
-
Download
PDBx/mmCIF format | ![]() | 636.5 KB | Display | ![]() |
---|---|---|---|---|
PDB format | ![]() | 504.5 KB | Display | ![]() |
PDBx/mmJSON format | ![]() | Tree view | ![]() | |
Others | ![]() |
-Validation report
Summary document | ![]() | 2.8 MB | Display | ![]() |
---|---|---|---|---|
Full document | ![]() | 2.9 MB | Display | |
Data in XML | ![]() | 95.6 KB | Display | |
Data in CIF | ![]() | 144.4 KB | Display | |
Arichive directory | ![]() ![]() | HTTPS FTP |
-Related structure data
-
Links
-
Assembly
Deposited unit | ![]()
|
---|---|
1 |
|
-
Components
-Protein , 1 types, 3 molecules ABC
#1: Protein | Mass: 72756.375 Da / Num. of mol.: 3 Source method: isolated from a genetically manipulated source Details: Envelope glycoprotein gp160 with V703-0537_T278M_L14 SOSIP engineered mutations Source: (gene. exp.) ![]() ![]() ![]() |
---|
-Antibody , 4 types, 12 molecules GJOIMQLNRHKP
#2: Antibody | Mass: 25043.186 Da / Num. of mol.: 3 Source method: isolated from a genetically manipulated source Source: (gene. exp.) ![]() ![]() #3: Antibody | Mass: 22937.352 Da / Num. of mol.: 3 Source method: isolated from a genetically manipulated source Source: (gene. exp.) ![]() ![]() #4: Antibody | Mass: 22957.490 Da / Num. of mol.: 3 Source method: isolated from a genetically manipulated source Source: (gene. exp.) ![]() ![]() #5: Antibody | Mass: 24541.561 Da / Num. of mol.: 3 Source method: isolated from a genetically manipulated source Source: (gene. exp.) ![]() ![]() |
---|
-Sugars , 5 types, 45 molecules 
#6: Polysaccharide | 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose Source method: isolated from a genetically manipulated source #7: Polysaccharide | Source method: isolated from a genetically manipulated source #8: Polysaccharide | Source method: isolated from a genetically manipulated source #9: Polysaccharide | Source method: isolated from a genetically manipulated source #10: Sugar | ChemComp-NAG / |
---|
-Details
Has ligand of interest | N |
---|---|
Has protein modification | Y |
-Experimental details
-Experiment
Experiment | Method: ELECTRON MICROSCOPY |
---|---|
EM experiment | Aggregation state: PARTICLE / 3D reconstruction method: single particle reconstruction |
-
Sample preparation
Component | Name: G002-480-0546 Fab in complex with V703-0537_T278M_L14 SOSIP and BG18 Fab Type: COMPLEX / Entity ID: #1-#5 / Source: MULTIPLE SOURCES |
---|---|
Molecular weight | Experimental value: NO |
Buffer solution | pH: 7.4 |
Specimen | Conc.: 5.6 mg/ml / Embedding applied: NO / Shadowing applied: NO / Staining applied: NO / Vitrification applied: YES |
Specimen support | Grid type: UltrAuFoil R1.2/1.3 |
Vitrification | Instrument: FEI VITROBOT MARK IV / Cryogen name: ETHANE / Humidity: 100 % / Chamber temperature: 277 K |
-
Electron microscopy imaging
Microscopy | Model: TFS GLACIOS |
---|---|
Electron gun | Electron source: ![]() |
Electron lens | Mode: BRIGHT FIELD / Nominal magnification: 190000 X / Nominal defocus max: 1800 nm / Nominal defocus min: 800 nm / Alignment procedure: COMA FREE |
Specimen holder | Cryogen: NITROGEN / Specimen holder model: FEI TITAN KRIOS AUTOGRID HOLDER |
Image recording | Electron dose: 45 e/Å2 / Film or detector model: TFS FALCON 4i (4k x 4k) |
-
Processing
EM software |
| ||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
CTF correction | Type: PHASE FLIPPING AND AMPLITUDE CORRECTION | ||||||||||||||||||||||||
Symmetry | Point symmetry: C3 (3 fold cyclic) | ||||||||||||||||||||||||
3D reconstruction | Resolution: 3.4 Å / Resolution method: FSC 0.143 CUT-OFF / Num. of particles: 51495 / Symmetry type: POINT | ||||||||||||||||||||||||
Refinement | Highest resolution: 3.4 Å Stereochemistry target values: REAL-SPACE (WEIGHTED MAP SUM AT ATOM CENTERS) | ||||||||||||||||||||||||
Refine LS restraints |
|